Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN)

A secondary analysis of randomised controlled trial - CALGB/alliance 170601

E. M L Smith, H. Pang, C. Ye, C. Cirrincione, S. Fleishman, E. D. Paskett, T. Ahles, L. R. Bressler, N. Le-Lindqwister, C. E. Fadul, Charles Lawrence Loprinzi, C. L. Shapiro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response.

Original languageEnglish (US)
JournalEuropean Journal of Cancer Care
DOIs
StateAccepted/In press - 2015

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Randomized Controlled Trials
Drug Therapy
Pain
Placebos
Logistic Models
Duloxetine Hydrochloride

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • Duloxetine
  • Oxaliplatin
  • Pain

ASJC Scopus subject areas

  • Oncology

Cite this

Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN) : A secondary analysis of randomised controlled trial - CALGB/alliance 170601. / Smith, E. M L; Pang, H.; Ye, C.; Cirrincione, C.; Fleishman, S.; Paskett, E. D.; Ahles, T.; Bressler, L. R.; Le-Lindqwister, N.; Fadul, C. E.; Loprinzi, Charles Lawrence; Shapiro, C. L.

In: European Journal of Cancer Care, 2015.

Research output: Contribution to journalArticle

Smith, E. M L ; Pang, H. ; Ye, C. ; Cirrincione, C. ; Fleishman, S. ; Paskett, E. D. ; Ahles, T. ; Bressler, L. R. ; Le-Lindqwister, N. ; Fadul, C. E. ; Loprinzi, Charles Lawrence ; Shapiro, C. L. / Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN) : A secondary analysis of randomised controlled trial - CALGB/alliance 170601. In: European Journal of Cancer Care. 2015.
@article{7976641ea8f04a66bc6a5bbb7f0fce97,
title = "Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): A secondary analysis of randomised controlled trial - CALGB/alliance 170601",
abstract = "Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30{\%} reduction in pain; OR 4.036; 95{\%} CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response.",
keywords = "Chemotherapy-induced peripheral neuropathy, Duloxetine, Oxaliplatin, Pain",
author = "Smith, {E. M L} and H. Pang and C. Ye and C. Cirrincione and S. Fleishman and Paskett, {E. D.} and T. Ahles and Bressler, {L. R.} and N. Le-Lindqwister and Fadul, {C. E.} and Loprinzi, {Charles Lawrence} and Shapiro, {C. L.}",
year = "2015",
doi = "10.1111/ecc.12421",
language = "English (US)",
journal = "European Journal of Cancer Care",
issn = "0961-5423",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN)

T2 - A secondary analysis of randomised controlled trial - CALGB/alliance 170601

AU - Smith, E. M L

AU - Pang, H.

AU - Ye, C.

AU - Cirrincione, C.

AU - Fleishman, S.

AU - Paskett, E. D.

AU - Ahles, T.

AU - Bressler, L. R.

AU - Le-Lindqwister, N.

AU - Fadul, C. E.

AU - Loprinzi, Charles Lawrence

AU - Shapiro, C. L.

PY - 2015

Y1 - 2015

N2 - Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response.

AB - Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response.

KW - Chemotherapy-induced peripheral neuropathy

KW - Duloxetine

KW - Oxaliplatin

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=84949921225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949921225&partnerID=8YFLogxK

U2 - 10.1111/ecc.12421

DO - 10.1111/ecc.12421

M3 - Article

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 0961-5423

ER -